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Abstract
Antibiotic administration is the standard treatment for the bacterium Helicobacter pylori, the main causative agent of peptic
ulcer disease and gastric cancer. However, the long-term consequences of this treatment on the human indigenous
microbiota are relatively unexplored. Here we studied short- and long-term effects of clarithromycin and metronidazole
treatment, a commonly used therapy regimen against H. pylori, on the indigenous microbiota in the throat and in the lower
intestine. The bacterial compositions in samples collected over a four-year period were monitored by analyzing the 16S
rRNA gene using 454-based pyrosequencing and terminal-restriction fragment length polymorphism (T-RFLP). While the
microbial communities of untreated control subjects were relatively stable over time, dramatic shifts were observed one
week after antibiotic treatment with reduced bacterial diversity in all treated subjects in both locations. While the
microbiota of the different subjects responded uniquely to the antibiotic treatment some general trends could be observed;
such as a dramatic decline in Actinobacteria in both throat and feces immediately after treatment. Although the diversity of
the microbiota subsequently recovered to resemble the pre treatment states, the microbiota remained perturbed in some
cases for up to four years post treatment. In addition, four years after treatment high levels of the macrolide resistance gene
erm(B) were found, indicating that antibiotic resistance, once selected for, can persist for longer periods of time than
previously recognized. This highlights the importance of a restrictive antibiotic usage in order to prevent subsequent
treatment failure and potential spread of antibiotic resistance.
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Introduction
Within each anatomical niche in the human body, a complex,
specialized microbiota is found [1]. The normal intestinal
microbiota has several beneficial roles including protection against
pathogen invasion, development of the immune system, and in
nutrition [2,3,4,5,6]. Several external factors can cause distur-
bances or alter the bacterial composition. For example, antimi-
crobial treatment is known to cause short-term changes in the
composition of the normal human microbiota [7], but also long-
term consequences have been shown [8,9,10,11]. One concern
with the administration of antibiotics is the possibility of selection
of antibiotic resistant strains of bacteria; not only in those which
the antibiotic is directed towards but also among the normal
microbiota [10]. The human indigenous microbiota could thereby
potentially serve as a reservoir of resistance genes and contribute
towards antibiotic resistance development [12,13].
A commonly used treatment regimen for Helicobacter pylori,a
Gram negative rod colonizing the gastric mucosa, is a triple
therapy with clarithromycin, metronidazole, and omeprazole
[14,15,16]. This treatment can lead to antibiotic resistance
development among H. pylori strains [16] and also among
members of the normal microbiota [7,9,10,11,17]. One mecha-
nism for macrolide resistance is via erythromycin resistance
methylases encoded by erm genes. These genes have been found
in different genera with erm(B) having the largest host range [18].
The erm(B) gene is normally found on transposons located in the
chromosome or on plasmids [18] and encodes a ribosomal
methylase that methylates the 23S ribosomal RNA and thereby
prevents the antibiotic from binding [19].
A few reports [7,20,21] have described microbiological changes
following an eradication therapy containing clarithromycin,
metronidazole and omeprazole using traditional culture-based
methods. However, recent studies based on 16S rRNA gene
analysis have shown that about 60–80% of the bacterial
community in the intestine has not yet been cultured, in part
because of unknown growth requirements [22]. Therefore, the
impact of this commonly used antibiotic treatment therapy on the
majority of the human microbiota is not fully known, especially
not the long-term consequences.
Different molecular approaches have been applied to directly
assess the diversity and composition of human-associated bacterial
communities without the necessity for cultivation [22,23,24,25].
Most studies have focused on the gut environment, although an
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example, recently a highly diverse microbiota was found in the
throat [24] with 152 different phylotypes. The healthy microbiota
has also been characterized in the distal esophagus [26] and
stomach [27]. The largest number of bacteria is found in the colon
[25], where it has been estimated that approximately 10
11 bacteria
colonize 1 gram of feces [28].
One example of a DNA-based community fingerprinting
approach that has been used to study antibiotic effects on the
gut microbiota is terminal restriction fragment length polymor-
phism (T-RFLP) [29]. We previously used this approach to
monitor the impact of clindamycin administration on the fecal
microbiota [8]. Both short-term community shifts and long-term
impacts (i.e. 2 years) on the Bacteroides populations were observed.
In the present study, we used a combination of molecular
approaches to assess the impact of a commonly used antibiotic
treatment for H. pylori on the bacterial community composition in
throat and stool samples over a four-year time period. By using
16S rRNA gene pyrosequencing and T-RFLP we aimed to
determine whether antibiotic treatment resulted in long term shifts
in the microbial community structure in the samples. In addition,
we used real-time PCR to monitor erm(B) gene resistance levels up
to four years after treatment.
Results
Long-term stability of the indigenous microbiota
The T-RFLP and pyrosequencing results were highly comple-
mentary. T-RFLP provided a rapid overview of changes in
dominant members of the community, whereas the pyrosequen-
cing data provided in depth information about changes in relative
amounts of thousands of OTUs. Several thousand pyrosequencing
reads were analyzed in all patients and controls and approximately
5000–11000 pyrosequencing reads in either throat or feces were
analyzed per subject (Table S1).
The T-RFLP data were highly reproducible based on replicate
extractions from the fecal samples and restriction digestions with
three different restriction enzymes (data not shown). Overall the T-
RFLP results correlated well with the 454-pyrosequencing results
regarding the most dominant members of the microbiota. The most
dominant TRFs (HaeIII digestion; 272–276 bp) in the fecal
community were members of the Clostridium coccoides subgroupwithin
the Firmicutes phylum, according to the RDP database (Figures S1,
S2, and S3). The relative abundances of these TRFs were positively
affected in patient D and negatively affected in patients E and F. In
addition, the 285-bp TRF, corresponding to Enterococcus faecalis
according tothe RDPdatabase,became verydominantinpatientsE
and F immediately after treatment and represented more than 20%
of the fecal microbiota (Figures S2 and S3).
For analysis of the pyrosequencing data, the relative amounts of
the different phyla were first determined in the control group and
these amounts were used as a baseline for reference to subjects in
the treated group. The throat microbiota in all six samples was
dominated by five bacterial phyla; Firmicutes, representing 49% of
the pyrosequencing reads (mean value of the six individuals, for
individual values see Table S2), followed by Bacteroidetes (15%),
Actinobacteria (14%), Fusobacteria (6%) and Proteobacteria (5%)
(Fig. 1). The average fecal microbiota in all six samples was
dominated by four bacterial phyla; Firmicutes (78%) followed by
Actinobacteria (14%), Bacteroidetes (3%) and Proteobacteria (2%)
(Fig. 2; for individual values see Table S3). Overall, the most
dominant taxonomic groups at the genus level found in throat
samples were e.g. Streptococcus, Prevotella, Coprococcus, Actinomyces, and
Neisseria (Fig. 3A, Fig. S4A and Table S4). In fecal samples, the
most dominant taxonomic groups were e.g. Lachnospiraceae Incertae
Sedis, unclassified Lachnospiraceae, Bifidobacterium, Collinsella, unclas-
sified Ruminococcaceae (Fig. 3B, Fig. S4B, Table S4).
The microbiota of the untreated controls generally displayed
lower variation within individuals than between individuals at any
sampling period, as deduced by Bray-Curtis analysis of OTU
frequencies (Fig. 4 and Table 1), supporting previous reports
regarding a stable individual gut microbiota [1,23,30,31,32].
However, a decline in the individual gut microbiota similarity over
time was observed in the control group where higher similarities
were found in 5 of 6 samples collected on days 0 and 8–13
compared to day 0 and year 4 (Fig. 4, Table 1). Interestingly, the
throat microbiota composition was more similar between
individuals, suggesting that a more general and select microbiota
is found in the human throat. These data were supported using
correspondence analysis (CA), also based on OTU frequencies. In
the CA analyses no time dependent clustering was found for the
throat communities (Fig. 5A), however a time-dependent decline
in similarity for the fecal control samples (Fig. 6A).
Transient and persistent effects of antibiotic treatment
In contrast to the situation for the controls, the throat and fecal
microbiotas in treated patients differed considerably from their
pre-treatment compositions according to Bray-Curtis analysis
(Fig. 7A and 7B) and by CA analysis (Fig. 5B and 6B). The post
treatment sample (immediately after treatment) was separated
from the pre-treatment sample by CA axis 1, which describes the
largest variation, in all fecal samples and in two out of three throat
samples (Fig. 6B, 5B). One and four years after treatment, the fecal
microbial communities had partially recovered to their pre-
treatment compositions, however these were still separated along
CA axis 2 (Fig. 6B). The decline in similarity over time was
particularly evident for the fecal microbiota of patient F, and the
throat community of patient E (Table 1). The bacterial diversity
(Shannon diversity index) in the samples also decreased immedi-
ately following treatment (Table S5), which was also reflected in
the rarefraction curves (Figs. S5 and S6). This decline in diversity
was most pronounced in the fecal samples. However at the later
sampling periods the bacterial diversity was more similar to that
found prior to treatment (Table S5, Figs. S5 and S6).
Immediately after antibiotic treatment the average throat
microbiota of the three treated individuals were dominated mainly
by three bacterial phyla; Firmicutes (54%), Proteobacteria (33%),
and Fusobacteria (4%), whereas their fecal microbial communities
were dominated by only two phyla; Firmicutes (78%) and
Proteobacteria (19%) (For individual values see Tables S2 and
S3). The Actinobacteria levels were particularly reduced in the
throat and gut environments of all three subjects immediately after
antibiotic treatment (Figs. 1 and 2, Tables S2 and S3). This effect
was most pronounced in the fecal samples where the majority of
Actinobacteria belonged to the subclasses Actinobacteridae and
Coriobacteridae. Very few or no reads corresponding to
Bacteroidetes were detected in feces of the patients at day 0,
thereby negating the possibility to draw conclusions regarding the
impact of the treatment on this phylum.
Individuality in antibiotic response
In addition to the overall trends in community change, the
pyrosequencing data showed that specific members of the
microbiota of each individual were impacted differently by the
antibiotic treatment (Fig. 3A and B), presumably due to their
unique microbiota compositions prior to treatment. In general,
negatively affected taxonomic groups in throat samples were
Actinomyces and Prevotella in all samples, and Coprococcus in two of the
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taxonomic groups in the majority of the fecal samples were
Bifidobacterium, Collinsella, and Ruminococcus (Fig. 3B). Due to the
individual responses found, each individual will be separately
discussed in the following section.
Individual D. The throat sample showed a decrease in members
of the Firmicutes immediately after treatment to only 19% of the
total microbiota (Table S2). One genus negatively affected within
the Firmicutes was Coprococcus (from relative abundance 18% to
0%). The dominant phylum in the throat of this patient after
antibiotic treatment was instead Proteobacteria (61%), and
examples of positively affected taxonomic groups within this
phylum were Neisseria (from relative abundance 1% to 29%) and
unclassified Enterobacteriaceae (from relative abundance 0% to 28%)
(Fig. 3A). At the 1 and 4 year sampling times the throat microbiota
was dominated by four bacterial phyla: Firmicutes, Proteobacteria,
Actinobacteria, and Bacteriodetes. Also, the increase of the
unclassified Enterobacteriaceae persisted in this patient during the
4-year time period (Fig. 3A).
In feces, the major effect was a negative impact on some
members of the Actinobacteria, where Bifidobacterium and Collinsella
were the major taxonomic groups affected (Fig. 3B). A positive
impact in feces was seen for unclassified Lachnospiraceae that
increased in relative abundance from 19% to 48%.
Figure 1. Phyla distribution in throat samples. Pie charts showing the phyla found in throat samples at day 0, day 8–13, 1 and 4 years in three
controls (A, B, and C) and three antibiotic treated patients (D, E, and F). By using 16S rRNA pyrosequencing five different phyla were found in the
throat samples; Firmicutes, Proteobacteria, Actinobacteria, Bacteroidetes, and Fusobacteria.
doi:10.1371/journal.pone.0009836.g001
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Firmicutes increased in relative abundance from 53% to 81% in
the throat samples of this individual (Table S2). There was also an
increase in Proteobacteria post treatment that persisted and
continued to increase over time (Table S2). The relative
abundance of Neisseria also increased and persisted one year after
treatment (Fig. 3A). After treatment Haemophilus and Streptococcus
also increased from 1% to 9% and 28% to 71%, respectively, of
the community (Fig. 3A).
In the feces the Enterococcus sp. within the Firmicutes phylum
were positively affected immediately after treatment (Fig. 3B,
Fig. S2), as also seen in the T-RFLP data, and increased from
0 to 28% relative abundance. However, no sequences corres-
ponding to Enterococcus sp. were detected at the later sampling
periods.
Individual F. In the throat samples the relative abundances of
Actinobacteria and Bacteroidetes decreased and Fusobacteria,
Proteobacteria and Firmicutes increased after antibiotic treatment
(Table S2). Within the Actinobacteria and Bacteroidetes phyla,
Actinomyces and Prevotella in particular decreased in rela-
tive abundance from 10% to 0% and 12% to 3%, respectively
(Fig. 3A).
Figure 2. Phyla distribution in fecal samples. Pie charts showing the phyla found in fecal samples at day 0, day 8–13, 1 and 4 years in three
controls (A, B, and C) and three antibiotic treated patients (D, E, and F). By using 16S rRNA pyrosequencing four different phyla were found in fecal
samples; Firmicutes, Proteobacteria, Actinobacteria, and Bacteroidetes.
doi:10.1371/journal.pone.0009836.g002
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relative abundance after treatment (Fig. 3B). Similar to individual E,
the relative abundance of the Enterococcus sp. increased immediately
after antibiotic treatment, from 0% to 11% relative abundance
(Fig. 3B and Fig. S3) as also observed by T-RFLP, whereas unclas-
sified Lachnospiraceae decreased in relative abundance 29% to 0%.
Figure 3. Individualized antibiotic responses. The heat maps show the relative abundance per sample of different taxonomic groups found in
throat (A) or fecal (B) patient samples. The color panel shows the percent relative abundance (0–70%) of different taxonomic groups within the major
phyla (Actinobacteria, Bacteroidetes, Firmicutes, Fusobacterium and Proteobacteria) detected from patients at day 0 (1), day 8–13 (2), 1 year (3) and 4
years (4) after treatment.
doi:10.1371/journal.pone.0009836.g003
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The antibiotic resistance gene, erm(B), was not detected in the
throat samples of the treated individuals prior to treatment on day
0 (data not shown). Directly after antibiotic treatment the erm(B)
gene varied around baseline levels (range 8–400 fold increase) and
it persisted at this level up to 4 years. The erm(B) gene was also
detected in the three controls analyzed at all sampling occasions,
and these levels also varied around baseline levels (data not
shown).
There was also a low abundance or no detectable amount of
erm(B) in the fecal samples prior to treatment (data not shown). The
erm(B) gene also remained around baseline levels in the fecal
samples from the controls, except in subject A, that had a
detectable increase in the 1 year sample (Fig. 8A). By contrast, the
erm(B) gene levels increased dramatically by 3 to 5 orders of
magnitude in the antibiotic treated subjects immediately after
treatment (Fig. 8B). After 1 year, there was still over a 1000-fold
increase in erm(B) levels in all three patients and the persistence was
Figure 4. Correlation plots for the controls. Correlation plots showing OTU frequency at day 0 (x-axis), and day 8–13, 1 and 4 years (y-axis) in
throat (A) and fecal (B) samples in the controls (A, B, and C). Bray-Curtis values are indicated as numbers in the figure as a number. A Bray Curtis value
of 0 suggest the two sites have the same composition and 1 means the two sites do not share any species. The color of the dots represent different
phyla: yellow, Actinobacteria; green, Bacteroidetes; blue, Firmicutes; red, Proteobacteria; grey, other phyla. Percentages of inter-sample variation
explained by the two axes are shown in the figures.
doi:10.1371/journal.pone.0009836.g004
Table 1. Intra-and inter-subject Bray-Curtis values for throat and fecal samples.
Intra-subject Throat Intra-subject Feces
Day 0 vs.
day 8–13
Day 0 vs.
1 year
Day 0 vs.
4 years
Day 0 vs.
day 8–13
Day 0 vs.
1 year
Day 0 vs.
4 years
A 0.46 0.45 0.62 A 0.39 0.52 0.65
B 0.45 0.42 0.51 B 0.37 0.65 0.74
C 0.44 0.40 0.43 C 0.36 0.46 0.50
D 0.77 0.47 0.48 D 0.80 0.66 0.71
E 0.75 0.66 0.84 E 0.80 0.67 0.69
F 0.72 0.42 0.45 F 0.99 0.85 0.86
Inter-subject Throat Mean value 6 standard deviation Inter-subject Feces Mean value 6 standard deviation
A–B 0.5360.07 A–B 0.6860.06
A–C 0.5960.11 A–C 0.8260.04
B–C 0.5860.10 B–C 0.8660.05
A Bray Curtis value of 0 means the two sites has the same composition and 1 means the two sites do not share any species. Controls (A, B, C) and patients (D, E, F). For
the inter-subject Bray-Curtis value, all samples and time points were compared and a mean Bray-Curtis value was calculated.
doi:10.1371/journal.pone.0009836.t001
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9836Figure 5. Correspondence analysis of the bacterial community found in throat samples. Each correspondence analysis plot represents the
relative abundance values for the OTUs from the 16S rRNA pyrosequencing at day 0, day 8–13, 1 and 4 years. A: Controls; A, B, and C. B: Antibiotic
treated patients; D, E, and F. Percentages of inter-sample variation explained, by the two axes are shown in the figures. In controls A–C and patients
D–F the third axis represented 25%, 27%, 26%, 22%, 24%, and 20% of the variation.
doi:10.1371/journal.pone.0009836.g005
Figure 6. Correspondence analysis of the bacterial community found in fecal samples. Each correspondence analysis plot represents the
relative abundance values for the OTUs from the 16S rRNA pyrosequencing at day 0, day 8–13, 1 and 4 years. A: Controls; A, B, and C. B: Antibiotic
treated patients; D, E, and F. Percentages of inter-sample variation explained, by the two axes are shown in the figures. In controls A–C and patients
D–F the third axis represented 19%, 17%, 20%, 26%, 20%, and 20% of the variation.
doi:10.1371/journal.pone.0009836.g006
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especially in patients D and F (Fig. 8B).
Discussion
We used a combination of molecular approaches to monitor
ecological disturbances of the human microbiome in individuals
treated with clarithromycin and metronidazole. We found that
treatment with clarithromycin and metronidazole had a long-term
impact on the gut microbiota. A lower diversity of the gut
microbiota was found in the throat and fecal samples immediately
after treatment. However, the patient number was too few to
calculate whether these observations were significant or not. For
future studies it would be valuable to analyze more samples before
onset of treatment for each individual to establish a better baseline.
Previous studies using cultivation-based approaches have shown
that these antibiotics resulted in short-term ecological effects on
the indigenous gut microbiota [7,20,21]. Adamsson et al. [7]
found that the numbers of culturable Bifidobacterium, Clostridium,
and Bacteroides spp. significantly decreased in feces after treatment,
while the numbers of enterococci significantly increased one week
after treatment. They also detected a persistent decrease of
Bifidobacterium sp. and Bacteroides sp. 4 weeks after treatment. The
molecular approaches that we used enabled us to explore the
impact of treatment in more depth compared to cultivation. As
previously described [7], we also found relative decreases in
members of the genera Clostridia and Bifidobacteria and increases in
the enterococci in fecal samples from treated individuals.
Negligible sequences corresponding to Bacteroidetes were detected
in feces collected from patients at day 0. This could be due to bias
in the DNA extraction method used, although Bacteroidetes have
previously been detected at abundant levels in fecal samples from
other individuals using the same extraction methods [8] and
amplification protocols [29] in our group. Another possibility is
Figure 7. Correlation plots for the patients. Correlation plots showing OTU frequency at day 0 (x-axis), day 8–13, 1 and 4 years (y-axis) in throat
(A) and fecal (B) samples in the patients (D, E, and F). Bray-Curtis values are indicated as numbers in the figure. A Bray Curtis value of 0 suggest the
two sites have the same composition and 1 that the two sites do not share any species. The colors of the dots represent different phyla: yellow,
Actinobacteria; green, Bacteroidetes; blue, Firmicutes; red, Proteobacteria; grey, other phyla.
doi:10.1371/journal.pone.0009836.g007
Figure 8. erm(B) abundance over time. The normalized fold
increase of erm(B) compared to day 0 in community DNA extracted
from fecal samples for controls (A–C) not receiving any treatment (A)
and patients (D–F) receiving antibiotics (B). Each bar graph represents
the mean and standard error of the normalized expression of erm(B)
compared to 16S. Normalization was carried out as previously been
described [8].
doi:10.1371/journal.pone.0009836.g008
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individuals, since it has previously been shown that this phylum
has strong inter-subject variability [23]. The 16S rRNA primers
used for the pyrosequencing in the present study were evaluated in
a previous study and showed no specific bias regarding
Bacteroidetes [24].
A few recent studies have pointed to an underestimation of
Actinobacteria in feces in relation to other phyla due to primer
bias [24,33], but the primers used in the present study successfully
amplified Actinobacteria [24]. Increasing evidence has linked
some members of the Actinobacteria to human health [34,35]. For
example, an increased abundance of Actinobacteria has recently
been associated with obesity [36]. Although only a limited number
of studies have been conducted to date, together they highlight the
importance of studying Actinobacteria in more detail. In the
present study we found that Actinobacteria were strongly reduced,
especially in feces, by a commonly used antibiotic treatment.
We studied the impact of the antibiotic regimen on the
microbiota in the throat in addition to the gut. The oral cavity has
a large surface area with several distinct niches; each suggested to
harbor a specific bacterial microbiota according to a recent study
of the healthy microbiota in different body sites [37]. Our results
indicate that the throat microbiota was more similar between
individuals and more stable after antibiotic treatment and over
long periods than the intestinal microbiota, suggesting that the
throat environment is more selective for a specific microbiota.
Other studies have also found that the most common genera in the
throat and oral cavity are members of the Streptococcus, Gemella,
Veillonella, Actinomyces, Rothia, Neisseria and Prevotella [24,37]. The
oral microbiota has been shown to closely resemble that found in
the distal esophagus and suggested to contain a complex but
conserved bacterial community [26].
The effects of treatment that were observed on the bacterial
communites in the throat and feces might be due to either
clarithromycin or metronidazole or both in combination.
However, there are some differences in the target bacteria for
the two antibiotics. The decrease of Actinobacteria is probably due
to clarithromycin, which have representatives known to be
susceptible to this antibiotic [38], while they are naturally resistant
to metronidazole ((http://www.srga.org/). By contrast, metroni-
dazole is known to be active against anaerobic bacteria and both
antibiotics are active against Streptococcus. It is also important to
highlight that macrolide excretion is primarily accomplished
through bile, approximately 20–30% is excreted through the
urine and the rest is excreted through feces. For metronidazole
10–15% is excreted into feces and the rest is excreted by urine
(http://www.srga.org/).
The antibiotic treatment impacted the indigenous microbiota
differently in the individual treated subjects, probably due to the
known unique bacterial community compositions in different
individuals [1,23,30,31,32]. We found that the microbial commu-
nities were more similar at both sampling locations within
individuals than between individuals, at least up to the one year
sampling period. This unique individual community composition
was particularly evident for the fecal samples where larger
differences were observed between individuals. There was also a
pronounced temporal change in fecal community structure and
after four years the gut communities had diverged in both the
control group and the treated group.
Recent studies have shown that some antibiotics have long-term
impacts on the fecal microbiota [8,9,10,11,17,39,40]. For example,
clindamycin treatment resulted in a lower Bacteroides diversity in
fecal samples, an enrichment of resistant Bacteroides clones,
specifically B. thetaiotamicron, and an increase in resistance erm-genes
up to two years after treatment [8]. Long-term impacts (six months)
were also recently seen in the gut microbiota after treatment with
ciprofloxacin [39]. Although the majority of the gut microbiota
returned to pretreatment levels after four weeks, some taxa failed to
recover to pretreatment levels for periods up to 6 months.
Another clear indication of a persistent impact of the antibiotic
treatment on the gut microbiota was a marked increase of erm(B)
gene levels in the fecal samples that persisted up to four years after
treatment. The increase and persistence of erm(B) can either be
explained by clonal expansion of stable, resistant isolates originally
present in the intestinal microbiota pretreatment, or by erm(B)
acquisition by new populations via horizontal gene transfer.
Epidemic spread of erm(B) has been shown to be the cause of
increased macrolide resistance in Streptococcus pyogenes [41]. Our
results suggest a link between erm(B) gene levels and the increase in
enterococci after treatment, indicating that the enterococci might
be the bearers of antibiotic resistance. Highly macrolide-resistant
enterococci have previously been reported to be selected by
treatment with clarithromycin and metronidazole as evidenced by
the increase in erm(B) levels in cultured enterococci after treatment
[10]. One resistant clone persisted for three years without any
further antibiotic pressure [10].
This is one of the first studies to our knowledge to thoroughly
follow the dynamics of the throat microbiota over time in healthy
individuals and following antibiotic treatment. Recently it was
reportedthatclarithromycintreatmentselectsformacrolide-resistant
bacteria in the throat microbiota [17], supporting the findings we
present here. Interestingly, we found that erm(B) was detected in
throat samples from both patients and controls in the present study,
although not in a high abundance in the controls. The detection of
low levels of erm(B) in the control samples could be explained by
previous exposure to macrolides before inclusion in the study.
In conclusion, a common one-week antimicrobial treatment
regimen with clarithromycin and metronidazole resulted in
marked ecological disturbances in the throat and gut microbiota
with potential long-term consequences. The molecular approaches
that we used enabled a more detailed monitoring of ecological
disturbances due to antibiotic treatment that has previously been
possible using conventional cultivation techniques. In total, the
observations in the present study underline the importance of
restrictive and proper use of antibiotics in order to prevent long-
term ecological disturbances of the indigenous microbiota. In
hospital environments, a decreased colonization resistance and
persistence of antibiotic resistance could potentially lead to an
overgrowth and spread of multi-resistant potential pathogenic
bacteria and thereby increase the risk of treatment failure.
Materials and Methods
Ethics statement
Written consent was obtained from all participants involved in
the study and the study was approved by written consent by the
human ethics committee at Uppsala University, Uppsala, Sweden.
Subjects and treatment
Six individuals were included in this study: three control
patients (A, B, and C), hereafter referred to as controls, with
diagnosed dyspeptic disorders who did not receive any treatment
and three patients (D, E, and F) that had either a gastric or
duodenal ulcer and were treated twice a day for seven days with
metronidazole 400 mg, clarithromycin 250 mg, and omeprazole
20 mg (Supplementary Table S6 for subject info). None of the
patients had received any antibiotic treatment within four weeks
prior to the start of the study and during the four-year course of
Long-Term Antibiotic Impacts
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patients did not receive any diet restrictions or recommendations
before inclusion into the study. A throat swab and a fecal sample
were collected from each subject one day before treatment,
immediately after (Control A: 13 days, control B: 12 days, control
C: 13 days, patient D: 12 days, patient E: 8 days, patient F: day 10)
and one and four years after treatment. All samples were stored at
270uC until analyzed. This material was part of a larger
longitudinal cohort study where the aim was to study eradication
of H. pylori using a common treatment regimen [11].
DNA extraction
DNA was extracted from 250–500 ml throat samples from each
subject. The throat samples were diluted (1:1) in a 20 mM Tris-
HCI (pH 8.0) and 2 mM sodium EDTA buffer and spun for
10 min at 50006g. The samples were lysed in 180 ml lysozyme
buffer (20 mM Tris-HCI, pH 8.0, 2 mM sodium EDTA, 1.2%
Triton X-100, and 20 mg/ml lysozyme (Sigma-Aldrich, Schnell-
dorf, Germany) and incubated at 37uC for 1 h. Proteinase K and
200 ml Buffer AL from Qiagen’s DNeasy Tissue Kit (Qiagen,
Hilden, Germany) were added and the mixture was incubated at
56uC for 16 h followed by DNA extraction using Qiagen’s
DNeasy Tissue Kit (Qiagen), according to the manufacturer’s
instructions. DNA was extracted from duplicate 100 mg fecal
samples from each subject using a FastDNA SPIN Kit for Soil
(BIO 101, Carlsbad, Calif.) according to the manufacturer’s
instructions. The bead-beating step was performed in a FastPrep
instrument (BIO 101) for 2 times 20 s at speed 5.5.
16S rRNA tag pyrosequencing
The 16S rRNA genes were amplified in a 50 ml reaction
containing 1X PCR-buffer, 200 mM dNTP PurePeak DNA
polymerase Mix (Pierce Nucleic Acid Technologies, Milwaukee,
WI, USA), 500 mM of each primer (SGS, Ko ¨ping, Sweden) and
2.5 U of PfuUltra High-Fidelity DNA polymerase (Stratagene La
Jolla, CA, USA). The primer pairs used, targeting the V6 region of
the 16S rRNA gene, were 784f with adaptor B and 1061r with
adaptor A and sample-specific sequence barcodes (for primer,
adaptor,and barcodesequences,seeSupplementaryTable S7)[24].
To each reaction 1 ml of the extracted template DNA was added.
The PCR conditions used were 95uC for 5 min, 25 cycles of 95uC
for40 sec,55uCfor40 secand 72uCfor1 min followedby72uCfor
7 min. Three amplification reactions were performed for each
sample and then pooled together. The PCR-products with a
proximal length of 300 bp were excised from a 1% agarose gel
stained with ethidium bromide and purified using a QIAquick gel
extraction kit (Qiagen). The DNA concentration and quality were
assessed on a Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using
a DNA1000lab chip (Agilent). Equal DNAamounts of four samples
with different sample specific barcode sequences were pooled to a
final concentration of 10 ng/ml. The pooled DNA wereamplified in
PCR-mixture-in-oil emulsions and sequenced on different lanes of a
16-lane PicoTiterPlate on a Genome Sequencer FLX system
(Roche, Basel, Switzerland) at the Swedish Institute for Infectious
Disease Control (Solna, Sweden). In additon to the standard
sequence quality filtering applied by the instrument software,
pyrosequencing reads were removed that 1) did not include a
correct primer sequence, 2) were shorter than 200 bp (excluding the
primer sequence) and 3) included any ambiguous bases. The
resulting reads were finally trimmed to 200 bp (excluding primer).
Taxonomic classification
The 200 bp trimmed pyrosequencing reads were aligned and
clustered into operational taxonomic units (OTUs) with complete
linkage clustering at maximum within-cluster distance of 3% using
the RDP pyrosequencing pipeline (http://rdp.cme.msu.edu/).
The most abundant 454 sequence (one per group of identical
sequences) within one OTU were BLAST searched with default
parameters against a local database comprising 269,420 near full-
length bacterial 16S rRNA gene sequences from the Ribosomal
Database Project (RDP) v. 10.7 [42]. The sequences inherited the
taxonomic annotation (down to genus level) of the best scoring
RDP hit fulfilling the criteria of $95% identity over an alignment
of length $180 bp. If no such hit was found the sequence was
classified as ‘‘no match’’. Details regarding primer design is found
in a previous publication [24]. Rarefraction analysis on the throat
and fecal microbiota was performed using Analytical Rarefraction
1.3 (http://www.uga.edu/strata/software/).
T-RFLP
16S rRNA genes were amplified in the DNA extracts using the
eubacterial primers fD1-FAM [43] labeled at the 59 end with 6-
carboxyflourescein and 926r [44] (for primer sequences, see
Supplementary Table S8). All primers were synthesized by
Invitrogen (Carlsbad, Calif.) Amplification was carried out in a
50 ml reaction mixture containing 2.5 U of Taq DNA polymerase
(Amersham Biosciences, Uppsala, Sweden), 1X PCR Buffer
(Amersham Biosciences), 0.7 mmol of each primer, 10 nmol of
each deoxynucleoside triphosphate (Amersham Pharmacia Bio-
tech), 2.5 ml dimethyl sulfoxide, sterile distilled water, and 1 mlo f
template DNA. The cycling program was performed in a Perkin-
Elmer GeneAmp PCR system 2400 thermocycler using the
following conditions: 95uC for 5 min followed by 25 cycles of
95uC for 40 s, 55uC for 40 s, and 72uC for 1 min. The last cycle
ended with an elongation step for 7 min. The restriction enzyme
digestions, electrophoresis conditions and calculations were
performed as previously described [29].
Real-time PCR
The abundance of erm(B) genes was analyzed in the throat and
fecal samples. The 16S rRNA gene was used as a reference gene.
Primers and probes were designed using Primer Express software
2.0 (ABI). The erm(B) gene was amplified using ermBf/ermBr and a
TaqMan probe (ABI). The 16S rRNA genes were amplified using
16Sf/16Sr and a TaqMan probe. The fluorescent reporter dye at
the 59 end of the probe was 6-FAM; the quencher at the 39 end was
a black-hole quencher-1 (BHQ-1). For primer and probe sequences,
see Supplementary Table S8. All primers were synthesized using
Invitrogen (Carlsbad, Calif.) and the probes were synthesized using
Thermo Electron GmbH (Ulm, Germany). The cycling program
was performed on an ABI Prism 7900HT (ABI) under the following
conditions: 2 min at 50uC, 10 min at 95uC, followed by 40 cycles of
15 s at 94uC and 1 min at 60uC. The PCR mixture without
template DNA was included in each run as a negative control. The
results were analyzed using the software SDS 2.1 (ABI). In the
present study we normalized the erm(B) gene copiesto the number of
16S copies and preparation of curves and calculations were carried
out as previously described [8].
Statistical analysis and diversity estimations
Shannon diversity index was calculated as 2S log(pi)pi [45],
where pi denotes the frequency of phylotype. Significance was
tested using Wilcoxon t-test in the R software (http://www.r-
project.org/). Bray-Curtis similarity was also calculated using the
R software. Correspondence analysis (CA) was performed on the
pyrosequencing data using the General Rweb interface (http://
pbil.univ-lyon1.fr/Rweb/). The relative abundance values of each
OTU were used in the calculation and scatter plots were created.
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Supporting Information
Figure S1 T-RFLP peaks from patient D fecal sample. Relative
abundance values of TFRs obtained using the general eubacterial
16S rRNA primers fD1 and 926r and HaeIII restriction digestion
for patient D. The 273-bp TRF represents members of Clostridium
coccoides subgroup such as Clostridium clostridiiforme ATCC 25537
and Eubacterium formicigenerans ATCC 27755 and the 275-bp TRF
represents Eubacterium ramulus ATCC 29099, Eubacterium rectale
ATCC 33656, Eubacterium ventriosum ATCC 27560, and Roseburia
cecicola ATCC 33874.
Found at: doi:10.1371/journal.pone.0009836.s001 (0.81 MB
TIF)
Figure S2 T-RFLP peaks from patient E fecal sample. Relative
abundance values of TFRs obtained using the general eubacterial
16S rRNA primers fD1 and 926r and HaeIII restriction digestion in
patient E. The 273-bp TRF represents members of Clostridium
coccoides subgroup such as Clostridium clostridiiforme ATCC 25537 and
Eubacterium formicigenerans ATCC 27755 and the 275-bp TRF
representsEubacteriumramulusATCC29099,EubacteriumrectaleATCC
33656, Eubacterium ventriosum ATCC 27560, and Roseburia cecicola
ATCC 33874. The 285-bp TRF represents Enterococcus faecalis.
Found at: doi:10.1371/journal.pone.0009836.s002 (0.34 MB
TIF)
Figure S3 T-RFLP peaks from patient F fecal sample. Relative
abundance values of TFRs obtained using the general eubacterial
16S rRNA primers fD1 and 926r and HaeIII restriction digestion
in patient F. The 273-bp TRF represents members of Clostridium
coccoides subgroup such as Clostridium clostridiiforme ATCC 25537
and Eubacterium formicigenerans ATCC 27755 and the 275-bp TRF
represents Eubacterium ramulus ATCC 29099, Eubacterium rectale
ATCC 33656, Eubacterium ventriosum ATCC 27560, and Roseburia
cecicola ATCC 33874. The 285-bp TRF represents Enterococcus
faecalis. The 242-bp TRF was unidentified.
Found at: doi:10.1371/journal.pone.0009836.s003 (0.36 MB
TIF)
Figure S4 Taxonomic groups found in throat or fecal samples.
The heat maps show the relative abundance per sample of different
taxonomic groups found in throat or fecal control samples. The
color panel shows the percent relative abundance (0–70%) of
different taxonomic groups within the major phyla (Actinobacteria,
Bacteroidetes, Firmicutes, Fusobacterium and Proteobacteria)
detected in throat (A) and fecal (B) samples from controls at time
points: day 0 (1), day 8–13 (2), 1 year (3) and 4 years (4).
Found at: doi:10.1371/journal.pone.0009836.s004 (0.20 MB
TIF)
Figure S5 Rarefraction analysis of throat samples. Number of
phylotypes sampled as a function of number of reads in controls
(A–C) and patients (D–F). Sampling time points: A=Day 0,
B=Day 8–13, C=1 year, D=4 years.
Found at: doi:10.1371/journal.pone.0009836.s005 (0.45 MB
TIF)
Figure S6 Rarefraction analysis of fecal samples. Number of
phylotypes sampled as a function of number of reads in controls
(A–C) and patients (D–F). Sampling time points: A=Day 0,
B=Day 8–13, C=1 year, D=4 years.
Found at: doi:10.1371/journal.pone.0009836.s006 (0.44 MB
TIF)
Table S1 Number of reads, OTUs and genus per individual (A–F).
Found at: doi:10.1371/journal.pone.0009836.s007 (0.04 MB
DOC)
Table S2 Individual relative abundance values (%) for the
dominant phyla found in throat samples over time. The sequences
inherited the taxonomic annotation (down to genus level) and the
best scoring RDP hit fulfilling the criteria of $95% identity over
an alignment of length $180 bp. If no such his was found the
sequence was classified as ‘‘no match’’.
Found at: doi:10.1371/journal.pone.0009836.s008 (0.05 MB
DOC)
Table S3 Individual relative abundance values (%) for dominant
phyla found in fecal samples over time. The sequences inherited
the taxonomic annotation (down to genus level) and the best
scoring RDP hit fulfilling the criteria of $95% identity over an
alignment of length $180 bp. If no such his was found the
sequence was classified as ‘‘no match’’.
Found at: doi:10.1371/journal.pone.0009836.s009 (0.04 MB
DOC)
Table S4 Dominant taxonomic groups found in throat- and
fecal samples. The relative abundance (in percentage) of the 20
most dominant taxonomic groups found throat and fecal samples,
respectively. The abundance of all OTUs belonging to the same
genus, or were unclassified at the same taxonomic level, were
summed.
Found at: doi:10.1371/journal.pone.0009836.s010 (0.04 MB
DOC)
Table S5 Diversity estimations. Shannon diversity index was
calculated based on OTU frequency. The diversity index
decreased at day 8–13 in both throat- and fecal samples following
antibiotic treatment while it remained stable within the controls
during the whole time period.
Found at: doi:10.1371/journal.pone.0009836.s011 (0.04 MB
DOC)
Table S6 Features of participants included in the study.
Found at: doi:10.1371/journal.pone.0009836.s012 (0.03 MB
DOC)
Table S7 Oligonucleotides, adaptor, and sample specific
barcode sequences for 16S rRNA sequencing.
Found at: doi:10.1371/journal.pone.0009836.s013 (0.03 MB
DOC)
Table S8 Oligonucleotides for terminal-restriction fragment
length polymorphism and real-time PCR.
Found at: doi:10.1371/journal.pone.0009836.s014 (0.03 MB
DOC)
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